The National Cancer Institute is looking for clinical trial participants with Glypican-3 positive HHC, a type of liver cancer, to receive an experimental therapy of genetically modified CAR-T cells. Study treatment consists of a preparative regimen with standard chemotherapy drugs fludarabine and cyclophosphamide and CAR-T cell infusion. Researchers want to see if this treatment can help people with a certain type of liver cancer. NIH will cover study-related costs for medical care, travel and housing. For more information on specific inclusion and exclusion criteria, visit https://go.usa.gov/xtErY or call 866-444-2214 (TTY users dial 7-1-1) and reference study #21-C-0030.
Are you interested in participating in research as a healthy volunteer? Willing to undergo a bronchoscopy to help advance tuberculosis (TB) research? The National Heart, Lung, and Blood Institute (NHLBI) is conducting a study to evaluate airway immunity in adults with a positive or negative TB skin test. Want to participate? Contact our NIH Clinical Center Office of Patient Recruitment at 866-444-2214 (TTY users dial 7-1-1) or ccopr@nih.gov or visit https://go.usa.gov/xM4mH. Refer to study number 21-H-0027.
NIAID researchers are enrolling healthy volunteers 18-29 living in the DC, Maryland and Virginia areas in an investigational Epstein-Barr virus (EBV) vaccine clinical trial. If you are eligible, consider joining to help research into stopping the spread of EBV – the most common cause of infectious mononucleosis (mono) and associated with some cancers. For more information contact the NIH Clinical Center Office of Patient Recruitment at 866-444-2214 (TTY users dial 7-1-1), ccopr@nih.gov or visit https://go.usa.gov/xsYK5. Refer to study #21-I-0005.
